A review by Piccininë et al. in March 2019 reported that the expression of PPARGC1A was decreased in NAFLD, and the expression of PPARGC1A was negatively correlated with the severity of NAFLD [49]. This evidence concerns the gene PPARGC1A and metabolic dysfunction-associated steatotic liver disease.